CDT · CDT Equity Inc.
$3.27
-0.11 (-3.25%)
At close · Jul 23
Going-concern doubt
— flagged Jul 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern for at least the next 12 months from the financial statement filing date.”View the 10-Q filed Jul 15, 2026
Market Cap
$19.31M
Shares
6.31M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$39.22M
-120.3%
FY2025
Diluted EPS
-$11,778.90
+98.1%
FY2025
Operating Cash Flow
-$15.56M
-60.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $4.92M | $5.05M | $3.38M | $90K | $37K | — | |
| $31.88M | $31.7M | $12.04M | $5.17M | $3.05M | — | |
| $36.8M | $36.76M | $15.42M | $5.26M | $3.16M | — | |
| -$36.8M | -$36.76M | -$15.42M | -$5.26M | -$3.16M | — | |
| — | $200K | $32K | — | $100K | $100K | |
| — | — | — | $15K | $1.98M | — | |
| -$1.74M | -$2.47M | -$2.38M | $4.73M | -$1.73M | — | |
| — | — | — | — | -$129K | — | |
| — | -$39.22M | -$17.8M | -$536K | $773.5K | — | |
| — | — | — | — | $374.86K | — | |
| -$38.53M | -$39.22M | -$17.8M | -$535K | -$4.89M | -$4381 | |
| — | -$39.22M | -$17.8M | -$535K | -$4.89M | — | |
| -$38.65M | -$39.65M | -$17.8M | -$799K | -$4.13M | — | |
| USD/shares | — | -$11,778.90 | -$615,986.20 | -$23,700.00 | -$390,000.00 | — |
| USD/shares | — | -$11,778.90 | -$615,986.20 | -$267,600.00 | -$390,000.00 | — |
| shares | — | 3330 | 28.9 | 22.3246 | 12.4826 | 0.9583 |
| shares | — | 3330 | 28.9 | 22.6313 | 12.4826 | 0.9583 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.41×
EV/EBIT
—
Biotechnology median 26.60×
P/E (TTM)
0.00×
Biotechnology median 7.07×